Evidence map›Paper›PMID 42148094›Full record

ArticleFrontiers in immunology2026

Correction: Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma.

Shanshan Xu, Feiran Chen, Lei Diao, Weiyu Wang, Xuemin Wang, Qiong Wu, Peipei Sun, Yating Hao, Yuqian Wang, Rongjie Ji and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Shanshan Xu *Department of Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Feiran Chen *Department of Urogenital Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Lei DiaoDepartment of Urogenital Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Weiyu WangDepartment of Urogenital Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Xuemin WangDepartment of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Qiong WuDepartment of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Peipei SunDepartment of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Yating HaoDepartment of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Yuqian WangDepartment of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Rongjie JiDepartment of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Yanan JiangDepartment of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Jun DuDepartment of Urogenital Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Bing AngDepartment of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Zhigang ZhaoDepartment of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Qing YangDepartment of Urogenital Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2026.1731920.].

Indexed as

advanced penile squamous-cell carcinomaimmune checkpoint inhibitorsneoadjuvant and/or adjuvant chemotherapyneoadjuvant chemotherapyprogrammed death-ligand 1

Identifiers

PMID42148094
PMCPMC13173300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.